CEOs, Senior Executives Highlight Expansions at the DCAT Member Company Announcement Forum

CEOs and senior executives from DCAT Member Companies highlighted their companies’ major news at the DCAT Member Company Announcement Forum at DCAT Week.

CEOs and senior executives from DCAT Member Companies highlighted their companies’ major news at the DCAT Member Company Announcement Forum at DCAT Week.

By Patricia Van Arnum, Editorial Director, DCAT, pvanarnum@dcat.org 

CEO and senior executives from DCAT Member Companies highlighted their companies’ major news at the DCAT Member Company Announcement Forum at DCAT Week, the flagship event of the Drug, Chemical & Associated Technologies Association (DCAT) and the premier event for the global bio/pharmaceutical business ecosystem. Companies reported the latest in expansion plans across the bio/pharmaceutical value chain: from drug substances (small-molecules and biologics) to drug products (solid dosage and injectable product forms) and packaging. In all, 20 companies took to the podium to make their announcements. The program kicked off DCAT Week on Monday March 23, 2026. 

Details of each company’s announcement can be found below. 

Recent Feature Articles

Small-Molecule CDMO Outlook: What Lies Ahead

By
At the mid-point in 2026, how are small-molecule CDMOs faring? Larger CDMOs are faring well while CDMOs in early-stage capabilities face some headwinds with more challenging biotech financing

Biotech IPOs: Who Is Topping the Class of 2026?

By
What companies are topping biotech IPOs in 2026? Parabilis Medicines with a focus on alpha-helical peptides and Kailera Therapeutics specializing in GLP-1s and related drugs for obesity are leading the way. By Patricia Van…

China: The Innovation Factor Coming Into Play

By
Pfizer’s $10.5-billion partnering deal with China’s Innovent Biologics is the latest deal between the bio/pharmaceutical majors and China-based innovator drug companies. Is China becoming a force in innovation?

Oncology Drug Market: The Ups and Downs 

By
ASCO’s Annual Meeting, held this week in Chicago, is when bio/pharma companies highlight the most promising in their cancer drug pipelines and portfolios. What is the outlook for the global oncology drug market?